A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
NCT ID: NCT00681525
Last Updated: 2010-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ABT-335 135 mg
ABT-335
One ABT-335 135 mg capsule QD for 10 days
B
Atorvastatin 80 mg and Ezetimibe 10 mg
Atorvastatin
One 80 mg tablet of atorvastatin QD for 10 days
Ezetimibe
One ezetimibe 10 mg tablet QD for 10 days
C
ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
ABT-335
One ABT-335 135 mg capsule QD for 10 days
Atorvastatin
One 80 mg tablet of atorvastatin QD for 10 days
Ezetimibe
One ezetimibe 10 mg tablet QD for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-335
One ABT-335 135 mg capsule QD for 10 days
Atorvastatin
One 80 mg tablet of atorvastatin QD for 10 days
Ezetimibe
One ezetimibe 10 mg tablet QD for 10 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Positive screens for drug and alcohol
* Pregnant or breast-feeding females
* Any history of surgery(ies) that might interfere with the gastrointestinal motility, pH or absorption
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 8087
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-367
Identifier Type: -
Identifier Source: org_study_id